Last update : 04/21/2021 | Version : 1 | ID : 73553
General | |
Identification | |
Detailed name | Collateral damage of the COVID-19 pandemic observed among patients receiving treatment with intravitreal (IVT) injections of antiangiogenic agents |
Sign or acronym | COVIDIV |
General Aspects | |
Medical area |
Ophthalmology |
Study in connection with Covid-19 |
Yes |
Pathology (details) | Exudative ARMD, diabetes, retinal vein occlusion (RVO), or other disorders causing macular oedema |
Scientific investigator(s) (Contact) | |
Name of the director | Mauget-Faÿsse |
Surname | Martine |
Address | Hôpital Fondation A. de Rothschild, PIC-CIC, 29 rue Manin 75019 PARIS |
Phone | 01 48 03 64 37 |
Organization | Foundation A. de Rothschild Hospital |
Collaborations | |
Participation in projects, networks and consortia |
No |
Funding | |
Governance of the database | |
Sponsor(s) or organisation(s) responsible | Foundation A. de Rothschild Hospital/Clinical Research Unit |
Organisation status |
Both |
Presence of scientific or steering committees |
No |
Additional contact | |
Name of the contact | VACHEY |
Surname | Patrick |
Address | Hôpital Fondation A. de Rothschild, PIC-CIC, 29 rue Manin 75019 PARIS |
Phone | 01 48 03 64 33 |
pvachey@for.paris | |
Organization | Hôpital Fondation A. de Rothschild |
Name of the contact | THEVENIN |
Surname | Sophie |
Address | Hôpital Fondation A. de Rothschild, PIC-CIC, 29 rue Manin 75019 PARIS |
Phone | 01 48 03 65 96 |
sthevenin@for.paris | |
Organization | Hôpital Fondation A. de Rothschild |
Main features | |
Type of database | |
Type of database |
Others |
Specify | Questionnaire at inclusion + follow-up data taken from the medical records |
Database recruitment is is made on the basis of: |
Medication(s) taken |
Database recruitment is carried out as part of an interventional study |
No |
Additional information regarding sample selection. | Patient information following their first visit after the first lockdown on 11/05/2021: Patients contacted by telephone or informed during appointments. |
Database objective | |
Main objective | Describe the changes in visual acuity among patients receiving treatment with repeat IVT injections of antiangiogenic agents during the COVID-19 epidemic, between September 2019 and May 2021 |
Inclusion criteria |
Patient aged 18 years and over
-Eye disorder requiring treatment with repeat IVT injections of antiangiogenic agents: Exudative ARMD, macular oedema associated with diabetes or secondary to retinal vein occlusion. -Initiation of treatment with repeat IVT injections before 01/10/2019 |
Population type | |
Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
Population covered |
Sick population |
Pathology | H35 - Other retinal disorders |
Gender |
Male Woman |
Geography area |
National |
Data collection | |
Dates | |
Date of first collection (YYYY or MM/YYYY) | 2020 |
Size of the database | |
Size of the database (number of individuals) |
[1000-10 000[ individuals |
Details of the number of individuals | 1,500 planned - actual number included: 233 |
Data | |
Database activity |
Current data collection |
Type of data collected |
Clinical data Declarative data |
Clinical data (detail) |
Direct physical measures |
Details of collected clinical data | Treatment with IVT injections, outcome of the treated disorder |
Declarative data (detail) |
Phone interview |
Details of collected declarative data | Questionnaire on visits during the lockdown |
Presence of a biobank |
No |
Procedures | |
Participant monitoring |
Yes |
Details on monitoring of participants | Follow-up with data in the medical records up to a year after resuming follow-up after 11/05/2021 |
Links to administrative sources |
No |
Promotion and access | |
Promotion | |
Access |
Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05